Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Indiana for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Indiana only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Indiana (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Henry Davis (NPI 1174597538)

Field	Value
Entity Type	Individual
Organization	Henry Davis
Address	2723 S 7th St
City	Terre Haute
State	IN
ZIP	47802
Taxonomy	Rheumatology Physician
NPI Enumerated	February 14, 2006

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

This provider reports $2.2M in lifetime Medicare revenue and no Medicaid billing on file, making the practice effectively single‑payer (Medicare) from a claims/revenue perspective; absence of Medicaid activity means state Medicaid managed-care and fee‑for‑service exposure is minimal to nil. The NPI was enumerated 2006-02-14 (~20 years ago), indicating long tenure in the Medicare program and a likely established local practice footprint.

Revenue is highly concentrated in a small number of high-cost drug administrations: the precomputed top‑3 Medicare codes account for 64.7% of this provider's total Medicare revenue. Those top three are J1602 ($620K, 27.9%), J0129 ($595.7K, 26.8%), and J9312 ($220.5K, 9.9%), indicating that biologic drug administration drives the majority of billed Medicare dollars.

The code mix and top revenue drivers are consistent with a rheumatology practice that administers in‑office biologic infusions and injections: high-revenue codes include J1602 (golimumab), J0129 (abatacept), J9312 (rituximab), Q5104 (infliximab biosimilar), and J1745 (infliximab). Coupled with infusion/administration codes such as 96365 and 96372, the pattern points to a service line structured around on‑site infusion capability and drug acquisition/administration rather than office visits alone.

Several codes place this provider well above typical national volumes for infusion administration and certain biologics: J1602 ranks #23 of 1041 providers nationally (98th percentile; notably above typical national volume) and 96365 ranks #193 of 8873 providers nationally (98th percentile; notably above typical national volume). Q5104 also ranks strongly at #16 of 178 providers (92th percentile), reinforcing that this clinician is a major national participant for selected infused products and associated administration services.

Not all high‑revenue drugs show the same competitive position: J0129 ranks #165 of 1221 providers nationally (87th percentile; typical, unremarkable volume) and J9312 ranks #140 of 317 providers nationally (56th percentile; typical, unremarkable volume), suggesting the practice is a dominant player for some agents (e.g., golimumab) but a more modest participant for others like rituximab. This mixed standing matters for benchmarking supplier contracts and for assessing leverage with manufacturers or distributors.

Administration and nursing throughput appear material to the business model: 96365 (initial infusion) shows 696 claims with $31.3K revenue (1.4%) and a 98th percentile rank (notably above typical national volume), while 96372 (therapeutic injection) shows 445 claims with $4.5K revenue (0.2%) and a 97th percentile rank (notably above typical national volume). Those high percentiles for administration codes indicate significant on‑site infusion capacity and recurring procedural volume beyond single one‑off injections.

Office E&M and procedural codes contribute a small share of revenue relative to drugs and infusions: 99213 accounts for $30.8K (1.4%) and 99214 for $26.5K (1.2%), and both are described as typical, unremarkable volume in the data despite moderate percentile ranks. This split—high drug/infusion revenue with comparatively modest E&M revenue—signals that payer negotiations and utilization management efforts will likely need to focus on high-cost biologic administrations rather than routine clinic visit volume.

From a payer risk and contracting perspective, the heavy concentration in a few biologic administrations (64.7% of Medicare revenue from the top three codes) means utilization shifts, price changes, or formulary decisions affecting those agents could materially impact spending with this provider. Coupled with zero Medicaid billing on file, the provider represents a concentrated Medicare exposure that should be evaluated for clinical appropriateness of infusion frequency, drug selection (including biosimilar uptake like Q5104), and site‑of‑service contracting opportunities.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

30 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J1602	Injection, golimumab, 1 mg, for intravenous use	62,000	$10	$620K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	18,050	$30	$595.6K
J9312	Injection, rituximab, 10 mg	3,500	$60	$220.5K
J0897	Injection, denosumab, 1 mg	9,300	$20	$167.4K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	5,220	$30	$151.4K
J3111	Injection, romosozumab-aqqg, 1 mg	17,640	$10	$123.5K
J1306	Injection, inclisiran, 1 mg	12,210	$10	$109.9K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	3,110	$20	$74.6K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	700	$50	$31.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	510	$60	$30.8K

Showing 1–10 of 30

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 30 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Indiana Distribution

Henry Davis — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Indiana

Full comparison — all codes billed, vs. state median

30 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	6	30	10,630	$30	$391.1K
J9312	3	10	3,700	$60	$209.1K
J3111	10	20	16,730	$10	$187.6K
J1602	1	20	9,500	$10	$167.1K
Q5104	1	10	5,220	$30	$150.3K
J1745	12	20	3,990	$30	$119.4K
J1306	1	10	8,810	$10	$82.6K
J0897	21	220	2,730	$20	$74.9K
96413	39	120	140	$90	$19.1K
99214	2,203	10,540	110	$80	$15.5K

Showing 1–10 of 30

Related Providers

Other providers that share a Tax Identification Number (TIN) with Henry Davis, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Providence Medical Group LLC	IN	Multi-Specialty Clinic/Center	$0	$7.3M
Neil Kabous	IN	Cardiovascular Disease Physician	$326.6K	$0
Nawar Mercho	IN	Cardiovascular Disease Physician	$309.5K	$0
Tony Nasser	IN	Cardiovascular Disease Physician	$217.5K	$28.2K
Elias Dalloul	IN	Cardiovascular Disease Physician	$228.7K	$0
Antwan Mardini	IN	Internal Medicine Physician	$222.7K	$0
Sang Huh	IN	Hematology & Oncology Physician	$190.8K	$800
George Bittar	IN	Cardiovascular Disease Physician	$187.8K	$0
Melhem Jabbour	IN	Hematology & Oncology Physician	$160.3K	$0
Isaiah Pittman	IN	Endocrinology, Diabetes & Metabolism Physician	$155.6K	$2.2K

Nearby Providers

Other providers in the same ZIP code as Henry Davis, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Summit Bhc Henryville, LLC	IN	Substance Abuse Rehabilitation Facility	$0	$90.6M
Ambulance Management Services Ltd	IN	Land Ambulance	$2.9M	$14.7M
Terre Haute Regional Hospital, L.P.	IN	General Acute Care Hospital	$0	$16.7M
Gibault, Inc.	IN	Psychiatric Residential Treatment Facility	$0	$13.5M
Mosaic	IN	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$8.2M
City Optical Co., Inc.	IN	Optometrist	$0	$5.9M
Happiness Bag Players, Incorporated	IN	Developmentally Disabled Services Day Training Agency	$0	$5.8M
Wabash Valley Children's Dentistry	IN	Dentist	$0	$5.7M
City Of Terre Haute	IN	Land Ambulance	$669K	$4.4M
Terre Haute Pulmonary & Pediatric Clinic, LLC	IN	Critical Care Medicine (Internal Medicine) Physician	$0	$4.8M

Henry Davis — Billing Profile & Reimbursement Data

Sign up for Henry Davis — Billing Profile & Reimbursement Data policy alerts

Henry Davis — Billing Profile & Reimbursement Data

Sign up for Henry Davis — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References